141
Participants
Start Date
July 31, 2016
Primary Completion Date
June 30, 2020
Study Completion Date
June 30, 2020
Tadalafil
Tadalafil is an FDA approved, clinically-available drug that inhibits the enzyme phosphodiesterase type 5A (PDE5). Subjects who are randomized to this arm will be provided with 20mg of Tadalafil to take every day for 12 weeks, beginning at their baseline visit.
Placebo
100 patients will be randomized to receive a placebo pill. Subjects in this arm will be provided with 20mg Placebo to take every day for 12 weeks, beginning at their baseline visit.
Vanderbilt University Medical Center, Nashville
Vanderbilt University Medical Center
OTHER